Show simple item record

dc.contributor.authorHellesnes, Ragnhild
dc.contributor.authorKvammen, Øivind
dc.contributor.authorMyklebust, Tor Åge
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorKarlsdottir, Åsa
dc.contributor.authorNegaard, Helene Francisca Stigter
dc.contributor.authorTandstad, Torgrim
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorFosså, Sophie Dorothea
dc.contributor.authorHaugnes, Hege Sagstuen
dc.identifier.citationInternational Journal of Cancer. 2019, 1-12.nb_NO
dc.description.abstractUsing complete information on total treatment burden, this population‐based study aimed to investigate second cancer (SC) risk in testicular cancer survivors (TCS) treated in the cisplatin era. The Cancer Registry of Norway identified 5,625 1‐year TCS diagnosed 1980–2009. Standardized incidence ratios (SIRs) were calculated to evaluate the total and site‐specific incidence of SC compared to the general population. Cox regression analyses evaluated the effect of treatment on the risk of SC. After a median observation time of 16.6 years, 572 TCS developed 651 nongerm cell SCs. The SC risk was increased after surgery only (SIR 1.28), with site‐specific increased risks of thyroid cancer (SIR 4.95) and melanoma (SIR 1.94). After chemotherapy (CT), we observed 2.0‐ to 3.7‐fold increased risks for cancers of the small intestine, bladder, kidney and lung. There was a 1.6‐ to 2.1‐fold increased risk of SC after ≥2 cycles of cisplatin‐based CT. Radiotherapy (RT) was associated with 1.5‐ to 4.4‐fold increased risks for cancers of the stomach, small intestine, liver, pancreas, lung, kidney and bladder. After combined CT and RT, increased risks emerged for hematological malignancies (SIR 3.23). TCS treated in the cisplatin era have an increased risk of developing SC, in particular after treatment with cisplatin‐based CT and/or RT.nb_NO
dc.publisherohn Wiley & Sons Ltd on behalf of UICCnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleContinuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin eranb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.journalInternational Journal of Cancernb_NO
dc.description.localcode© 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.nb_NO
cristin.unitnameInstitutt for klinisk og molekylær medisin

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal